OrthoBiologics

1. Autologous blood; platelet-rich plasma and platelet-poor plasma<br>2. Defining, measuring and optimizing platelet-rich plasma<br>3. Optimal use of platelet-rich plasma and plateletpoor plasma<br>4. Where orthobiologics started: what are mesenchymal stem cells?<br>5. Bone marrow-derived mesenchymal stromal cells<br>6. Defining, optimizing, and measuring bone marrow aspirate and bone marrow concentrate<br>7. Optimal clinical use of bone marrow aspirate and bone marrow aspirate concentrate<br>8. Adipose mesenchymal stromal cells<br>9. Defining, optimizing, measuring, and utilizing adipose, MFAT, etc.<br>10. Optimal clinical use of adipose mesenchymalstromal cells<br>11. Basic science and preclinical evidence for amniotic membrane2derived allografts in<br>12. Defining, optimizing, and measuring amniotic/ placental mesenchymal stem cells<br>13. Optimal clinical use of amniotic/placental mesenchymal stem cells<br>14. Synovial mesenchymal stem cells<br>15. Peripheral blood stem cells<br>16. Orthobiologics—growth factors and mediators<br>17. Orthobiologics in the procedure room—who, what, where, when, and how<br>18. Orthobiologics in the operating room—who, what, where, when, and how<br>19. The changing regulatory environment: regulations and restrictions<br>20. Bioscaffolds for osteochondral injuries of the knee<br>21. Orthobiologics on the horizon<br>22. Complications associated with orthobiologics